This CPD activity is sponsored by Reckitt. All content is the true, accurate and independent opinion of the speakers and the views expressed are entirely their own.[/caption]
Sources: Australasian College of Pharmacy. Management of reflux: a guideline for pharmacists. Queensland Health. Queensland Community Pharmacy Gastro-oesophageal Reflux and Gastro-oesophageal Reflux Disease – Clinical Practice Guideline. NSW Health. NSW Pharmacist Practice Standards for gastro-oesophageal reflux and gastro-oesophageal reflux disease.[/caption]
Dr Ming S Soh PhD, BPharm (Hons)[/caption]
Mr Sotirios Temopoulos had a medical history that included multiple myeloma with a myelomataus lesion in his cervical spine, in which he was prescribed a fentanyl patch and pregabalin for neuropathic pain.
He also lived with a deep vein thrombosis, pulmonary embolism, meningitis, liver steatosis, depression, pre-diabetes, metabolic syndrome, chronic renal impairment, hypercholesteraemia, and had suffered a stroke.
At the time of his death, Mr Temopoulos received a weekly DAA from Quality Pharmacy in a separate DAA to those of his wife, Ekaterini.
In his DAA were:
- metabolic syndrome
- colecalcirerol
- coloxyl with senna
- oxycodone
- escitalopram
- atorvastatin
- pantoprazole
- aspirin
- valaciclovir
- lenalidomide
- oxycodone/naloxone (Targin).
Earlier in July 2020, Mr Temopoulos began taking lenalidomide, a chemotherapy drug, for his multiple myeloma, which was infused at Box Hill Hospital once a month. However, on 20 July, after a fall from his bed, he could not attend due to increasing back and kidney pain which were later diagnosed as lumbar spine fractures and he spent several days in hospital.
